Adalimumab-adbm and CYLTEZO® are the exact same medicine. The FDA first approved CYLTEZO as an interchangeable biosimilar (50 mg/mL) to Humira on October 15, 2021. …

Jun 4, 2025 · Cyltezo (adalimumab-adbm) is an interchangeable biosimilar of Humira; it is a TNF alfa inhibitors used to reduce pain, inflammation, and skin symptoms in autoimmune conditions.

Discontinue CYLTEZO if a patient develops a serious infection or sepsis during treatment. Perform test for latent TB; if positive, start treatment for TB prior to starting CYLTEZO. Monitor …

Jul 25, 2023 · Yes, Cyltezo is similar to Humira. Both drugs contain the active ingredient adalimumab-adbm.* This is a biologic medication, which means it’s made from parts of living …

Nov 5, 2025 · SERIOUS INFECTIONS - Patients treated with adalimumab products, including CYLTEZO, are at increased risk for developing serious infections that may lead to …

Adalimumab is used to reduce pain and swelling due to certain types of arthritis (such as rheumatoid, psoriatic, juvenile idiopathic, ankylosing spondylitis). This medication is also used …

CYLTEZO is a TNF-blocker medicine that can lower the ability of your immune system to fight infections.

May 13, 2024 · Our Cyltezo (adalimumab-adbm injection) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this …

Dec 5, 2025 · Note: This document provides detailed information about Cyltezo Side Effects associated with adalimumab. Some dosage forms listed on this page may not apply …

Discontinue CYLTEZO if a patient develops a serious infection or sepsis during treatment. Perform test for latent TB; if positive, start treatment for TB prior to starting CYLTEZO. Monitor …